Page last updated: 2024-11-13
lff571
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
LFF571: an antibacterial agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 42638236 |
CHEMBL ID | 2063705 |
SCHEMBL ID | 18391833 |
SCHEMBL ID | 18392088 |
MeSH ID | M0575065 |
Synonyms (16)
Synonym |
---|
3U2Q |
lff-571 |
CHEMBL2063705 |
j3.333.591a , |
lff571 |
unii-w7aul2r95z |
lff 571 |
W7AUL2R95Z , |
1160959-55-6 |
SCHEMBL18391833 |
SCHEMBL18392088 |
DB13013 |
Q27292430 |
CS-0016947 |
HY-19906 |
AKOS040748742 |
Research Excerpts
Overview
LFF571 is a novel semisynthetic thiopeptide antibacterial that is undergoing investigation for safety and efficacy in patients with moderate Clostridium difficile infections. L FF571 is an exploratory agent that inhibits EF-Tu.
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" There were no deaths, no serious adverse events, and no subject withdrawals due to an adverse event." | ( A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Grunenberg, N; Leeds, JA; Pertel, P; Praestgaard, J; Ting, LS; Yang, JC, 2012) | 0.58 |
" LFF571 was generally safe and well tolerated." | ( Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Blais, J; Bressler, A; Buitrago, M; Dabovic, K; Lee, C; Leeds, JA; Mullane, K; Pertel, P; Praestgaard, J; Weiss, K, 2015) | 1.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (20)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID675929 | Antibacterial activity against Enterococcus faecalis NB04025 infected in CD1 mouse assessed as mouse survival up to 5 days | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675939 | Plasma concentration in Clostridium difficile infected golden syrian hamster at 20 mg/kg, po qd administered for 5 days measured at 3 hrs post dose | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675936 | Drug level in Clostridium difficile infected golden syrian hamster cecum at 20 mg/kg, po qd administered for 5 days measured at 1 hr post dose | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675935 | Antibacterial activity against Clostridium difficile ATCC 43255 infected in golden syrian hamster assessed as survival rate at 20 mg/kg, po qd administered days 1 to 5 measured on days 6 to 21 | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675921 | Antibacterial activity against Enterococcus faecium 7130724 by broth microdilution method | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675931 | Oral bioavailability in Sprague-Dawley rat | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675940 | Antibacterial activity against Clostridium difficile ATCC 43255 infected in golden syrian hamster assessed as decrease in toxin level in cecum after 21 days by ELISA | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675922 | Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675928 | Antibacterial activity against Staphylococcus aureus ATCC 49951 infected in CD1 mouse assessed as mouse survival up to 5 days | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675924 | Antibacterial activity against Streptococcus pyogenes ATCC BAA-595 by broth microdilution method | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675930 | Aqueous solubility of the compound at pH 7.4 by RP-HPLC analysis | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675925 | Antibacterial activity against Clostridium difficile ATCC 43255 by broth microdilution method | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675927 | Binding affinity to Escherichia coli GDPNP-labelled EF-Tu by surface plasmon resonance analysis | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675938 | Plasma concentration in Clostridium difficile infected golden syrian hamster at 20 mg/kg, po qd administered for 5 days measured at 1 hr post dose | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675934 | Antibacterial activity against Clostridium difficile ATCC 43255 infected in golden syrian hamster assessed as survival rate at 2 mg/kg, po qd administered days 1 to 5 measured on days 6 to 21 | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675933 | Antibacterial activity against Clostridium difficile ATCC 43255 infected in golden syrian hamster assessed as survival rate at 0.2 mg/kg, po qd administered days 1 to 5 measured on days 6 to 21 | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675926 | Inhibition of protein synthesis in Escherichia coli S30 extract at 2 uM after 75 mins by luciferase based luminescence assay relative to GE2270A | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675937 | Drug level in Clostridium difficile infected golden syrian hamster cecum at 20 mg/kg, po qd administered for 5 days measured at 3 hrs post dose | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID675923 | Antibacterial activity against Staphylococcus aureus A4.018 by broth microdilution method | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2012 | Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5 | Discovery of LFF571: an investigational agent for Clostridium difficile infection. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (25.00%) | 5.53% |
Reviews | 2 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (58.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections [NCT01232595] | Phase 2 | 109 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |